FDA outlines inspection overhaul, proposes IND reforms, and greenlights a disputed cancer therapy

FDA officials announced a plan to restructure the agency’s inspectional operations, aiming to make inspections more efficient and focused. The proposed changes include consolidating regional offices and updating inspection priorities.

Acting chief of the Center for Biologics Evaluation and Research said the agency will introduce measures to streamline IND submissions, hoping to attract early-stage biotech research to the United States.

The agency also granted approval to a cancer drug that had previously been rejected twice, sparking debate among clinicians and patient groups. The decision reflects the FDA’s willingness to reconsider data when new evidence is presented.